Trial Profile
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms PROTECT
- 24 Sep 2021 Status changed from active, no longer recruiting to discontinued due to single center study with low enrollment .
- 02 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.